tiprankstipranks
Advertisement
Advertisement
Crinetics downgraded to Neutral from Buy at UBS
PremiumThe FlyCrinetics downgraded to Neutral from Buy at UBS
12d ago
Nuvectis’ NXP100 Just Achieved the First Marketing Approval Ever for a Once-Daily Oral Factor B Inhibitor
Premium
TipRanks Newswire
Nuvectis’ NXP100 Just Achieved the First Marketing Approval Ever for a Once-Daily Oral Factor B Inhibitor
17d ago
What the $10B Crinetics Deal & $2.9B Soleno Acquisition Might Say About Palatin’s Rare-Obesity Opportunity
Premium
TipRanks Newswire
What the $10B Crinetics Deal & $2.9B Soleno Acquisition Might Say About Palatin’s Rare-Obesity Opportunity
18d ago
Crinetics downgraded to Hold from Buy at Stifel
PremiumThe FlyCrinetics downgraded to Hold from Buy at Stifel
1M ago
Crinetics downgraded to In Line from Outperform at Evercore ISI
Premium
The Fly
Crinetics downgraded to In Line from Outperform at Evercore ISI
1M ago
Crinetics downgraded to Hold from Buy at TD Cowen
Premium
The Fly
Crinetics downgraded to Hold from Buy at TD Cowen
1M ago
Crinetics downgraded to Hold from Buy at Jefferies
PremiumThe FlyCrinetics downgraded to Hold from Buy at Jefferies
1M ago
Wedbush sees BioCryst, Ascendis as potential next targets after Crinetics deal
Premium
The Fly
Wedbush sees BioCryst, Ascendis as potential next targets after Crinetics deal
1M ago
Crinetics downgraded to Hold from Buy at JonesResearch
Premium
The Fly
Crinetics downgraded to Hold from Buy at JonesResearch
1M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100